罗氟司特片是什么药？罗氟司特的作用和功效

What kind of medicine is Roflumilast? The EU approved it for the treatment of severe chronic obstructive pulmonary disease (COPD) and chronic bronchitis in July 2010, with the trade name Daxas; on February 28, 2011, the US FDA approved it for the treatment of severe COPD, with the trade name Daliresp. This becomes the first new oral drug approved globally for the treatment of COPD in more than a decade. The drug has been shown to inhibit inflammation associated with COPD in a novel way of acting. As a once-daily oral tablet, (roflumilast) is not only the first of a new treatment for severe COPD, but also the first oral anti-inflammatory drug for COPD patients. Its unique properties could help better treat patients with COPD: When combined with a bronchodilator to treat patients with the most severe forms of COPD, roflumilast provides the additional benefit of further reducing symptoms and rates of disease exacerbations, making it the first drug to target a specific phenotype of COPD in patients with severe airflow limitation associated with chronic cough and phlegm and a history of recurrent disease exacerbations.

: Roflumilast is a long-acting inhibitor of selective phosphodiesterase type 4 (PDE-4) and has anti-inflammatory effects. Phosphodiesterases are a family of enzymes including at least 11 subtypes of enzymes that catalyze the decomposition of the messenger molecules cyclic adenosine monophosphate and/or cyclic guanosine monophosphate. Phosphodiesterase-4 is a major cyclic adenosine monophosphate metabolic enzyme in inflammatory and immune cells, and phosphodiesterase-4 inhibitors have broad anti-inflammatory activities including inhibiting the release of inflammatory mediators and inhibiting immune cell activation. In addition, phosphodiesterase-4 inhibitors have also been shown to have therapeutic effects in animal models of airway inflammation.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.